Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

613

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Vaccines, Pneumococcal
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.

BIOLOGICAL

7-valent pneumococcal conjugate vaccine

Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.

DRUG

Pentavac

The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).

Trial Locations (45)

21000

Dijon

29200

Brest

33000

Bordeaux

33270

Floirac

33370

Blanquefort

Tresses Melac

33500

Libourne

37000

Tours

37300

Joué-lès-Tours

44150

Ancenis

51000

Châlons-en-Champagne

54000

Nancy

54270

Essey-lès-Nancy

54500

Vandœuvre-lès-Nancy

57100

Thionville

59650

Villeneuve-d'Ascq

59700

Marcq-en-Barœul

59910

Bondues

67000

Strasbourg

67100

Strasbourg

67380

Lingolsheim

67400

Illkirch-Graffenstaden

69005

Lyon

69007

Lyon

69120

Vaulx-en-Velin

69130

Écully

69600

Oullins

73600

Moûtiers

75571

Paris

76100

Rouen

76150

Maromme

76600

Le Havre

80000

Amiens

81000

Albi

83300

Draguignan

83600

Fréjus

84130

Le Pontet

85100

Les Sables-d'Olonne

93260

Les Lilas

94000

Créteil

94130

Nogent-sur-Marne

94400

Vitry-sur-Seine

94420

Le Plessis-Trévise

95140

Garges-lès-Gonesse

06300

Nice

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00366678 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants | Biotech Hunter | Biotech Hunter